Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blind, Controlled Phase III Non-inferiority Study Assessing Efficacy and Safety of VERITY-BCG in Management of Intermediate and High-risk Non-muscle Invasive Bladder Cancer (NMIBC) in BCG-naïve Patients.

NCT05037279 is registered in ClinicalTrials.gov with Verity Pharmaceuticals Inc. as lead sponsor.

NCT NCT05037279
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05037279 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blind, Controlled Phase III Non-inferiority Study Assessing Efficacy and Safety of VERITY-BCG in Management of Intermediate and High-risk Non-muscle Invasive Bladder Cancer (NMIBC) in BCG-naïve Patients.
Lead sponsor
Verity Pharmaceuticals Inc.
Phase
Phase 3
Overall status
Recruiting
Start date
April 24, 2024
Completion date
February 28, 2029
Enrollment
540 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, bladder cancer recurrent, neoplasm recurrence, non-invasive bladder urothelial carcinoma, urothelial carcinoma bladder, urothelial carcinoma recurrent